Woman turned away from pub for wearing Union Flag dress says: 'I'm a grandma'
Tanya Ostolski, 54, claims she was turned away from the Wetherspoon's boozer due to her outfit.
The events followed an anti-illegal immigration protest that took place in Nottingham town centre on Friday, July 25 which Tanya attended.
READ MORE: Americans baffled by Ireland's beloved chicken fillet roll and Cork's flag during visit
READ MORE: Galway Races dress code, bag policy and 'banned' items
The protest was sparked after Reform MP Lee Anderson made an unverified claim that a local man who was charged with rape was an asylum seeker.
After marching in the protest, Tanya made her way to the local Wetherspoon - The Picture House - but was denied entry due to her dress, despite putting away the flag she was carrying, she says.
The decision caused anger amongst some protesters who clashed with bouncers on Friday evening as they were also denied entry, they said. Tanya Ostolski in her patriotic dress with son Leon (Image: Tanya Ostolski / SWNS)
According to Nottinghamshire Live, a spokesperson for Wetherspoon confirmed the pub asked customers with flags and placards not to enter so as not to 'increase tension'.
Tanya said: 'I'm disgusted. I won't be going back there. I go in there all the time, and I wasn't causing any trouble. The whole day was a peaceful protest.
'I'm a grandma and I've never caused any bother. I just can't believe this was all over a flag - it was really upsetting. I didn't do anything wrong."
According to Tanya, she was first refused entry because she was carrying a St George's cross flag. But after putting the flag away, Tanya said she was still turned away from the pub.
She claimed witnesses had defended her – calling the bouncers actions 'unfair' as she wasn't 'causing any trouble'.
Tanya said: 'I had the flag tied around my waist. He said I couldn't come in and asked me to put the flag away. But I had flags all over my dress and then I was told I can't come in at all.
'I was really confused – it's just a flag. I asked for a valid reason. They just kept saying, 'you're not coming in'. I'm not aggressive and didn't want to cause trouble, so I just walked away. People came up to me and said it was really unfair. I've heard I won't be welcome back or I might be barred."
JD Wetherspoons has a 'no flag' policy which was prohibits the pubs from hanging the England flag – which had backlash from pubgoers during the 2018 football world cup.
But during the men's Euro 2024, the popular chain overturned it's policy and allowed the pubs to hang the England flag during the summer tournament.
According to Nottinghamshire Live, Wetherspoon spokesman Eddie Gershon commented in response to the incident in Sutton-in-Ashfield.
He said: "Pub managers have a duty under the licensing laws, and as a matter of common sense, to judge every situation on its particular circumstances.
'In this case, the pub manager felt that it was important not to increase tensions. Therefore, on this occasion the manager asked customers not to enter with flags or any placards."
For the latest breaking news and top stories from at home and abroad, visit our homepage
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Independent
16 hours ago
- Irish Independent
Pragmatist or featherweight? Ursula Von der Leyen blamed for bad deal on tariffs, but EU had no stomach for a fight
It was a tough week for Ursula von der Leyen. Sadly, the Hungarian prime minister, Viktor Orban – who was never, ever, going to do her a favour – touched a nerve when he dubbed the EU Commission president a 'featherweight' who had been 'eaten for breakfast' by the Americans.
Irish Examiner
21 hours ago
- Irish Examiner
Trump's global tariff agenda puts Ireland's pharmaceutical industry at serious risk
The whole world is in thrall to the whims of Donald Trump's tariff agenda, as it has been since the 47th president of the United States' swearing-in last January. We've learned a few uncomfortable truths along the way. Much of the early outcry from America's allies and trading partners surrounded the lack of economic logic to the imposition of tariffs – which are effectively a tax for Americans on foreign products, in theory making them less attractive to US consumers and heightening the allure of their own domestic suppliers. Critics said that the new regime would disrupt the world economy needlessly and perhaps bring about a global recession. That may well come to pass. The problem is that in this stand-off America has the greater wherewithal in terms of raw economic power. It holds the cards as Trump himself might say. And nations worldwide are beginning to fall into line, the EU just the latest after agreeing to a blanket 15% tariff on goods and services going forward. After President of the European Commission Ursula von der Leyen and US President Donald Trump agreed the trade deal, the spin is that the pain of those tariffs is worth it in order to avoid a global trade war. Also, 15% is better than 30% or worse, is the thinking. Photo:The spin is that the pain of those tariffs is worth it in order to avoid a global trade war. Also, 15% is better than 30% or worse, is the thinking. Whether that represents capitulation in the face of bullyboy tactics, given that little or nothing has been asked of the US in return, is a separate conversation. Ireland's pharmaceutical industry Here in Ireland we have a bigger problem though, and that problem is the pharmaceutical industry. That industry contributes massively to the economy here via billions of euro in corporation tax contributions, with about 90 companies employing 50,000 people in highly-paid roles. A total 30,000 of those jobs are with American firms. Should foreign pharmaceutical concerns exit Ireland the impact on the country would be catastrophic. The industry globally had pleaded with Trump for it to be exempted from any tariff regime, ostensibly for altruistic reasons – that lifesaving medicines shouldn't be subject to capricious taxation. At an EU level, the industry asked that the bloc not apply reciprocal tariffs, one wish that has at least been granted. Pfizer is one of the massive American pharmaceutical companies holding bases in Ireland, in this case Cork. File picture: Dan Linehan Oddly enough, in Trump's world of permanent grievance where everyone has been making a sucker of the United States for decades, the outsize presence the US pharmaceutical industry holds in Ireland is one situation on which he indisputably has a legitimate point. Drug prices in the US can retail for as much as five times what an EU citizen would pay. Meanwhile, American pharma firms make a pretty penny avoiding American tax by basing themselves here. Trump's protectionist agenda demands that those jobs and companies should return home. The Government has been worrying about and planning for a worst-case scenario in terms of tariffs on pharmaceuticals for months. Reaction from the pharma companies But what of the pharma industry itself? The official line from the Irish Pharmaceutical Healthcare Association (IPHA), the industry's lobby group here, is that it is reviewing the announcements coming out of Washington as and when they happen 'as key implications for the pharmaceutical sector remain uncertain'. A stance it's hard to argue with given the whole world has grown used to the haphazard nature of the Trump administration's demands. The European Federation of Pharmaceutical Industries and Associations (EFPIA) notes that tariffs are 'a blunt instrument that will disrupt supply chains, impact on investment in research and development, and ultimately harm patient access to medicines on both sides of the Atlantic'. It added that if the goal is to rebalance trade and ensure a 'fairer distribution' of how pharmaceutical innovation is financed, then 'there are more effective means than tariffs that would help'. Impact on pharma in Ireland The IDA, the body with prime responsibility for attracting foreign investment to Irish shores, says of the pharma implications that it 'welcomes' the deal made between Europe and the US, arguing it provides 'much-needed certainty for Irish, European and American businesses who together represent the most integrated trading relationship in the world'. 'We are very much reliant (on the US market), there's no arguing with that,' says one industry insider. Last year a massive €44bn in pharmaceutical products were exported directly from Ireland to the US. 'But when you stand back €100bn was exported globally. So half went to America, but it's not like all business went there, though it is certainly the biggest partner,' says the source. That doesn't mean that those massive American companies holding bases here – MSD, Pfizer, ELI Lilly, Johnson and Johnson etc – are about to up sticks on the back of the new tariff regime. 'They are not going to leave today or tomorrow, no. But it could definitely impact future investment decisions,' the source says. One of the problems is that a great deal of uncertainty still surrounds the 15% tariff agreement, particularly with regard to pharma. One of the Eli Lilly production buildings at its state-of-the-art facility in Dunderrow, Kinsale, Co Cork. For starters, most people concerned thought that the pharmaceutical industry wasn't to be included in the deal. Then about two hours after the deal was agreed European Commission president Ursula von der Leyen said it would be included, a point Trump appeared to back up. The following day the White House produced a 'fact sheet' describing how the new regime would work, and affirming the 15% rate for pharma. Except that the same sheet stated that the European Union would pay the tariff – which isn't how tariffs work. Then there is the Section 232 investigation which the US Department of Commerce initiated into the pharma industry in April – aiming to establish if how the pharmaceutical system worldwide currently functions impacts negatively on the US from a national security standpoint. Should the answer arrived at be a 'yes', then additional tariffs on pharma may well follow (such investigations typically take a minimum of six months to conclude, so we'll probably get an answer sometime towards the end of the year). 'Pharma plans in the long-term,' says Aidan Meagher, tax partner specialising in life sciences with consultants EY, noting that most pharma manufacturers will have been planning for this scenario for months and will have frontloaded stock into the American market, thus negating immediate impacts in the near term. He says that companies will be likely looking at 'dual sourcing' initiatives, supplying the American market from within the US itself and using Irish operations for its trade around the rest of the globe. 'Ireland needs to up its game' But Meagher says that it would be 'remiss' of Ireland, and the pharma industry here, to take a 'wait and see' approach, perhaps with the supposition that Trump's policies will last for the remaining three-and-a-half years of his term, and no longer. 'It is all about the next investment. A lot of these drugs only have patent protection for a certain life or longevity. Ireland needs to maintain investment and to incentivise the right kind of activity in terms of attracting that innovation,' he says. That means thinking outside the box in terms of tax credits for research and development, and improvements to infrastructure, particularly housing, Meagher says, areas in which we are notably lagging behind in terms of international competition. But he argues that the situation is far from a doomsday scenario. 'It's not as simple as that, it's a whole range of business factors that need to be considered – it's all about impacts for specific companies,' he says. 'It's not all necessarily doom and gloom. Companies have had plenty of time to consider this. And pharma companies are long-term thinkers. Ireland has had just two issues with the FDA (the US food and drug administration, responsible for approving new drugs) in its history. "The country has a strong reputation. These countries have invested significantly and Ireland is the owner of a lot of valuable intellectual property.' But it's certainly not a time to be complacent, Meagher argues. 'We have dropped down the competitiveness radar, and our competitors now aren't in the EU – they're in Switzerland, Singapore and the US itself. We need to be a top competitor for inward investment, and R&D and infrastructure will be critical. That is where Ireland needs to up its game.'
The Irish Sun
a day ago
- The Irish Sun
Donald Trump vows to unleash ‘every tool in our arsenal' in price row with British drug firms
DONALD Trump insists he will unleash 'every tool in our arsenal' if British drug companies don't cut their prices within 60 days. The US President waged war with a total of seventeen firms demanding 'binding commitments' to match the lower prices offered to developing countries. Advertisement The move comes as the White House hit dozens of countries with a fresh slew of tariffs including punishing levies on neighbour Canada. Two UK drug firms, AstraZeneca and GSK, caught up in the pharma row saw their share price drop as Trump aims to lower prices for American citizens. The move could even have damaging consequences for the NHS whose leverage with suppliers due to its size could be reduced. Mr Trump has demanded the firms apply their 'most favoured nation' rates to Medicaid which is the health system for low-income Americans. Advertisement READ MORE ON DONALD TRUMP He said: 'Make no mistake: a collaborative effort towards achieving global pricing parity would be the most effective path for companies, the government, and American patients. In a letter to the firms, he said: 'But if you refuse to step up we will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices. 'Americans are demanding lower drug prices, and they need them today.' Around £16 billion was wiped off shares in the sector across Europe as fears grow higher prices in the rest of the world will fund the US reductions. Advertisement Most read in The Sun Exclusive The move comes after Trump said back in May that he wanted drug prices in the US to be reduced by 80 per cent. Moment Trump 'throws shade' at Meghan and Harry during Starmer press conference But experts appeared wary that he has the authority to reduce prices and a previous effort in his first term failed in court. At the time, he said the tactics were 'subsidising socialism' abroad in paying for the same pills from the same factories, which led to spiralling prices at home. The warning came as Mr Trump signed an executive order applying a wave of tariffs to 68 countries and the European Union. Advertisement Canada was hit with levies – up to 35 per cent from 25 per cent - due to its lack of co-operation in stopping flow of illegal drugs and fentanyl into America. Their PM Mark Carney said that his country was 'making historic investments in border security to arrest drag traffickers and end migrant smuggling'. Switzerland will also keep negotiating with the US after their tariff rate hit 39 per cent, which was far higher than they anticipated. 1 Donald Trump is demanding drug firms cut their prices for US customers Credit: Rex Advertisement
